Company Description
Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company.
It operates through two segments, Biopharmaceutical Innovation and Strategic Investments. The company researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development.
Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.
It also develops FSD-PEA, which is in preparation for Phase 2 trial for the treatment of inflammatory diseases, such as mast cell activation syndrome; Lucid-PSYCH to treat major depressive disorder; and unbuzzd, a dietary supplement for the treatment of alcohol misuse.
In addition, the company maintains a portfolio of strategic investments comprising loans secured by residential property.
The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024.
Quantum BioPharma Ltd. was founded in 1998 and is headquartered in Toronto, Canada.
| Country | Canada |
| Founded | 1998 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 17 |
| CEO | Zeeshan Saeed |
Contact Details
Address: 55 University Avenue, Suite 1003 Toronto, ON M5J 2H7 Canada | |
| Phone | 833 571 1811 |
| Website | quantumbiopharma.com |
Stock Details
| Ticker Symbol | QNTM |
| Exchange | NASDAQ |
| Share Class | Class B Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001771885 |
| ISIN Number | CA74764Y2050 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Zeeshan Saeed | Co-Founder, Chief Executive Officer and Executive Non-Independent Co-Chairman |
| Anthony John Durkacz | Co-Founder and Executive Non-Independent Co-Chairman |
| Dr. Lakshmi P. Kotra BPHARM, Ph.D. | President and Director |
| Donal Carroll CPA | Chief Financial Officer |
| Nathan Coyle CPA | Controller |
| Dr. Andrzej Chruscinski M.D., Ph.D. | Vice President of Clinical and Scientific Affairs |
| Dr. Ashwini Joshi M.S. | Director of Pharmaceutical Development |
| Dr. Patrick Onyango Ph.D. | Director of Operations at U.S. |
| Jason David Sawyer | Head of Finance and Mergers and Acquisitions |
| Maryann Adesso | Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 22, 2026 | 6-K | Report of foreign issuer |
| Apr 2, 2026 | 6-K | Report of foreign issuer |
| Apr 1, 2026 | 6-K | Report of foreign issuer |
| Mar 30, 2026 | 6-K | Report of foreign issuer |
| Mar 27, 2026 | 6-K | Report of foreign issuer |
| Mar 26, 2026 | 20-F | Annual and transition report of foreign private issuers |
| Mar 26, 2026 | 6-K | Report of foreign issuer |
| Mar 23, 2026 | 6-K | Report of foreign issuer |
| Feb 3, 2026 | SCHEDULE 13G/A | Filing |
| Dec 23, 2025 | 6-K | Report of foreign issuer |